The collaboration will provide Amgen with additional assets to advance its portfolio optimally.

Amgen and AstraZeneca announce collaboration to develop and commercialize clinical-stage swelling portfolio jointly Amgen and AstraZeneca Plc, announced an agreement to jointly develop and commercialize five monoclonal antibodies from Amgen’s clinical irritation portfolio ). The firms believe all of the molecules possess novel profiles and offer the potential to provide important remedies across multiple indications in inflammatory illnesses. The collaboration will provide Amgen with additional assets to advance its portfolio optimally, and Amgen will take advantage of the strong respiratory, asthma and inflammation advancement expertise of MedImmune, AstraZeneca’s biologics arm reproductive function more info .